Pharmacological disruption of mouse social approach behavior: Relevance to negative symptoms of schizophrenia

Behavioural Brain Research

Volumn 252, Issue , 2013, Pages 405-414

  Hanks, Ashley N ^a   Dlugolenski, Keith ^a   Hughes, Zoë A ^a   Seymour, Patricia A ^a   Majchrzak, Mark J ^a  

^a PFIZER INC   (United States)

Author keywords

D Cycloserine; GABA; Mouse; Negative symptom; NMDA receptor; Social approach

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ALPRAZOLAM; AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; DIZOCILPINE; FLUMAZENIL; GLYCINE RECEPTOR AGONIST; HALOPERIDOL; KETAMINE; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; RISPERIDONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; LOCOMOTION; MALE; MOUSE; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIAL PROBLEM; VALIDATION PROCESS;

D-CYCLOSERINE; GABA; MOUSE; NEGATIVE SYMPTOM; NMDA RECEPTOR; SOCIAL APPROACH;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPYRETICS; CARBOLINES; CARRIER PROTEINS; DEXTROAMPHETAMINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; GABA ANTAGONISTS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; SOCIAL BEHAVIOR DISORDERS; TIME FACTORS;

EID: 84880155146     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.06.017     Document Type: Article

References (36)

1. Heresco-Levy U., Javitt D.C. Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophrenia Research 2004, 66:89-96.
2. Feifel D., Shilling P. Promise and pitfalls of animal models of schizophrenia. Current Psychiatry Reports 2010, 12:327-334.
3. Moore H. The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy. Schizophrenia Bulletin 2010, 36:1066-1072.
4. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nature Neuroscience 2010, 13:1161-1169.
5. Ellenbroek B.A., Cools A.R. Animal models for the negative symptoms of schizophrenia. Behavioural Pharmacology 2000, 11:223-233.
6. O'Tuathaigh C.M.P., Kirby B.P., Moran P.M., Waddington J.L. Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophrenia Bulletin 2010, 36:271-288.
7. File S.E., Seth P. A review of 25 years of the social interaction test. European Journal of Pharmacology 2003, 463:35-53.
8. Brodkin E.S., Hagemann A., Nemetski S.M., Silver L.M. Social approach - avoidance behavior of inbred mouse strains towards DBA/2 mice. Brain Research 2004, 1002:151-157.
9. Nadler J.J., Moy S.S., Dold G., Simmons N., Perez A., Young N.B., et al. Automated apparatus for quantitation of social approach behaviors in mice. Genes, Brain and Behavior 2004, 3:303-314.
10. Moy S., Nadler J., Young N., Perez A., Holloway L., Barbaro R., et al. Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains. Behavioural Brain Research 2007, 176:4-20.
11. Stephenson D., O'Neill S., Narayan S., Tiwari A., Arnold E., Samaroo H., et al. Histopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesis. Molecular Autism 2011, 2:7.
12. Silverman J.L., Smith D.G., Rizzo S.J.S., Karras M.N., Turner S.M., Tolu S.S., et al. Negative Allosteric Modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of Autism. Science Translational Medicine 2012, 4:131-151.
13. Jones H.M., Pilowsky L.S. Dopamine and antipsychotic drug action revisited. The British Journal of Psychiatry 2002, 181:271-275.
14. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987, 1:133-152.
15. Moghaddam B., Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37:4-15.
16. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annual Review of Pharmacology and Toxicology 2002, 42:165-179.
17. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research 1999, 33:523-533.
18. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
19. Coyle J.T. The GABA-glutamate connection in schizophrenia: which is the proximate cause. Biochemical Pharmacology 2004, 68:1507-1514.
20. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annual Review of Pharmacology and Toxicology 2001, 41:237-260.
21. Wassef A., Baker J., Kochan L.D. GABA Schizophrenia: a review of basic science and clinical studies. Journal of Clinical Psychopharmacology 2003, 23:601-640.
22. Yang M., Perry K., Weber M.D., Katz A.M., Crawley J.N. Social peers rescue autism-relevant sociability deficits in adolescent mice. Autism Research 2011, 4:17-27.
23. Brigman J.L., Ihne J., Saksida L.M., Bussey T., Holmes A. Effects of subchronic phencyclidine (PCP) treatment on social behaviors, and operant discrimination and reversal learning in C57BL/6J mice. Frontiers in Behavioral Neuroscience 2009, 3. Article 2.
24. Otto M.W., Basden S.L., McHugh R.K., Kantak K.M., Deckersbach T., Cather C., et al. Effects of d-cycloserine administration on weekly nonemotional memory tasks in healthy participants. Psychotherapy and Psychosomatics 2009, 78:49-54.
25. McFarlane H., Kusek G., Yang M., Phoenix J., Bolivar V., Crawley J. Autism-like behavioral phenotypes in BTBR T+tf/J mice. Genes, Brain and Behavior 2008, 7:152-163.
26. Halene T.B., Ehrlichman R.S., Liang Y., Christian E.P., Jonak G.J., Gur T.L., et al. Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes, Brain and Behavior 2009, 8:661-675.
27. Labrie V., Lipina T., Roder J. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology 2008, 200:217-230.
28. Seillier A., Giuffrida A. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behavioural Brain Research 2009, 204:410-415.
29. Grauer S.M., Pulito V.L., Navarra R.L., Kelly M.P., Kelley C., Graf R., et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. Journal of Pharmacology and Experimental Therapeutics 2009, 331:574-590.
30. Moy S.S., Nonneman R.J., Shafer G.O., Nikolova V.D., Riddick N.V., Agster K.L., et al. Disruption of social approach by MK-801, amphetamine, and fluoxetine in adolescent C57BL/6J mice. Neurotoxicology and Teratology 2013, 36:36-46.
31. Spielewoy C., Markou A. Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology 2003, 28:1106-1116.
32. Dlugolenski K., Graf R., Hughes ZA Evaluation of the effects of withdrawal from acute PCP on progressive ratio responding-relevance to negative symptoms of schizophrenia? program no. 924. 15. 2012 neuroscience meeting planner 2012, Society for Neuroscience, New Orleans, LA, [Online].
33. Elhardt M., Martinez L., Tejada-Simon M.V. Neurochemical, behavioral and architectural changes after chronic inactivation of NMDA receptors in mice. Neuroscience Letters 2010, 468:166-171.
34. Silverman J.L., Babineau B.A., Oliver C.F., Karras M.N., Crawley J.N. Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autism. Neuropharmacology 2013, 68:210-222.
35. A receptor: neurochemical, neurophysiological, and behavioral effects. CNS Drug Reviews 2007, 13:475-501.
36. Neill J.C., Barnes S., Cook S., Grayson B., Idris N.F., McLean S.L., et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacology and Therapeutics 2010, 128:419-432.